Roquefort Therapeutics plc

Roquefort Therapeutics plc is a biotechnology research company focused on developing innovative drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator implicated in cancer progression. Incorporated in 2020 and headquartered in London, United Kingdom, the firm operates within the healthcare sector, specifically the biotechnology industry, with a lean team of seven full-time employees led by CEO Stephen Paul West. Its primary mission centers on advancing research and experimental development in biotechnology, as classified under SIC code 72110, to create therapeutic solutions for oncology. Roquefort Therapeutics plc plays a niche role in the financial markets by representing early-stage biopharma innovation, where small-cap biotech firms like itself contribute to the pipeline of potential cancer treatments amid ongoing clinical advancements, such as extensions to licensing agreements for key assets. Previously known as Roquefort Investments PLC until late 2021, the company maintains an active status and continues to file regular accounts and confirmation statements with UK authorities. This positions it as a speculative interest in the broader ecosystem of medical research and drug discovery.